Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$119.07
al cierre: Aug 21 EDT
$119.30
0.230.19%
Pre-comercialización: 5:41 AM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Jazz Pharmaceuticals PLC ha un obiettivo di prezzo di consenso pari a $188, stabilito in base alle ultime valutazioni degli analisti di 19. Le ultime 3 valutazioni degli analisti sono state rilasciate da Needham, Morgan Stanley y Morgan Stanley il agosto 20, 2025, agosto 6, 2025 y julio 22, 2025. Con un obiettivo di prezzo medio di $176.33 tra le Needham, Morgan Stanley y Morgan Stanley, c'è un implicito 47.81% upside per Jazz Pharmaceuticals PLC da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Needham
Morgan Stanley
Baird
RBC Capital
Piper Sandler
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Jazz Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/20/2025 | 69.32% | Needham | $202 → $202 | Reiterates | Buy → Buy | |||
08/06/2025 | 35.79% | Morgan Stanley | $165 → $162 | Maintains | Overweight | |||
07/22/2025 | 38.31% | Morgan Stanley | $166 → $165 | Maintains | Overweight | |||
06/11/2025 | 69.32% | Needham | $202 → $202 | Reiterates | Buy → Buy | |||
06/03/2025 | 69.32% | Needham | $202 → $202 | Reiterates | Buy → Buy | |||
05/07/2025 | 29.92% | Baird | $167 → $155 | Maintains | Outperform | |||
05/07/2025 | 44.17% | RBC Capital | $182 → $172 | Maintains | Outperform | |||
05/07/2025 | 23.22% | Piper Sandler | $176 → $147 | Reiterates | Overweight → Overweight | |||
05/07/2025 | 39.15% | Morgan Stanley | $183 → $166 | Maintains | Overweight | |||
05/07/2025 | 67.64% | Needham | $200 → $200 | Reiterates | Buy → Buy | |||
04/10/2025 | 76.03% | Needham | $210 → $210 | Reiterates | Buy → Buy | |||
03/10/2025 | 81.89% | HC Wainwright & Co. | $200 → $217 | Maintains | Buy | |||
03/07/2025 | 53.39% | Morgan Stanley | $175 → $183 | Assumes | → Overweight | |||
03/07/2025 | 50.04% | UBS | $145 → $179 | Upgrade | Neutral → Buy | |||
03/06/2025 | 92.79% | Truist Securities | $220 → $230 | Maintains | Buy | |||
03/05/2025 | 76.03% | Needham | $210 → $210 | Reiterates | Buy → Buy | |||
02/27/2025 | 67.64% | Barclays | $190 → $200 | Maintains | Overweight | |||
02/26/2025 | 25.73% | Cantor Fitzgerald | $140 → $150 | Downgrade | Overweight → Neutral | |||
02/26/2025 | 47.53% | Piper Sandler | $163 → $176 | Reiterates | Overweight → Overweight | |||
02/26/2025 | 49.2% | RBC Capital | $179 → $178 | Maintains | Outperform | |||
02/26/2025 | 75.19% | JP Morgan | $200 → $209 | Maintains | Overweight | |||
02/26/2025 | 76.03% | Needham | $205 → $210 | Maintains | Buy | |||
02/13/2025 | 42.5% | Wells Fargo | $130 → $170 | Upgrade | Equal-Weight → Overweight | |||
12/12/2024 | 36.63% | Piper Sandler | $163 → $163 | Reiterates | Overweight → Overweight | |||
12/12/2024 | 50.04% | RBC Capital | $179 → $179 | Reiterates | Outperform → Outperform | |||
12/12/2024 | 73.51% | Needham | $207 → $207 | Reiterates | Buy → Buy | |||
12/10/2024 | 50.04% | RBC Capital | $179 → $179 | Reiterates | Outperform → Outperform | |||
11/22/2024 | 67.64% | HC Wainwright & Co. | $200 → $200 | Reiterates | Buy → Buy | |||
11/21/2024 | 73.51% | Needham | $207 → $207 | Reiterates | Buy → Buy | |||
11/21/2024 | 36.63% | Piper Sandler | $166 → $163 | Reiterates | Overweight → Overweight | |||
11/18/2024 | 35.79% | Baird | $154 → $162 | Maintains | Outperform | |||
11/07/2024 | 63.45% | TD Cowen | — | $200 → $195 | Maintains | Buy | ||
11/07/2024 | 73.51% | Needham | $207 → $207 | Reiterates | Buy → Buy | |||
10/23/2024 | 50.04% | RBC Capital | $175 → $179 | Maintains | Outperform | |||
10/04/2024 | 46.69% | RBC Capital | $174 → $175 | Maintains | Outperform | |||
09/10/2024 | 71.84% | Needham | $205 → $205 | Reiterates | Buy → Buy | |||
09/09/2024 | 17.35% | Cantor Fitzgerald | $140 → $140 | Reiterates | Overweight → Overweight | |||
08/19/2024 | 69.32% | JP Morgan | $190 → $202 | Maintains | Overweight | |||
08/01/2024 | 17.35% | Cantor Fitzgerald | $140 → $140 | Reiterates | Overweight → Overweight | |||
08/01/2024 | 39.15% | Piper Sandler | $188 → $166 | Maintains | Overweight | |||
08/01/2024 | 45.85% | RBC Capital | $175 → $174 | Maintains | Outperform | |||
08/01/2024 | 0.59% | Wells Fargo | $140 → $120 | Maintains | Equal-Weight | |||
08/01/2024 | 71.84% | Needham | $208 → $205 | Maintains | Buy | |||
08/01/2024 | 67.64% | HC Wainwright & Co. | $200 → $200 | Reiterates | Buy → Buy | |||
08/01/2024 | 29.09% | Baird | $160 → $154 | Maintains | Outperform | |||
07/12/2024 | 25.73% | Morgan Stanley | $160 → $150 | Maintains | Equal-Weight | |||
07/02/2024 | -5.28% | UBS | $117 → $113 | Maintains | Neutral | |||
06/20/2024 | 76.03% | Needham | $222 → $210 | Maintains | Buy | |||
06/05/2024 | 41.66% | Goldman Sachs | → $169 | Initiates | → Buy | |||
05/03/2024 | 67.64% | HC Wainwright & Co. | $200 → $200 | Reiterates | Buy → Buy | |||
05/03/2024 | 67.64% | Barclays | $230 → $200 | Maintains | Overweight | |||
05/02/2024 | 86.09% | Needham | $222 → $222 | Reiterates | Buy → Buy | |||
04/10/2024 | 50.88% | Cantor Fitzgerald | $180 → $180 | Reiterates | Overweight → Overweight | |||
03/22/2024 | 50.88% | Cantor Fitzgerald | $180 → $180 | Reiterates | Overweight → Overweight | |||
03/22/2024 | 59.26% | JP Morgan | $170 → $190 | Maintains | Overweight | |||
03/20/2024 | 84.41% | Needham | $220 → $220 | Reiterates | Buy → Buy | |||
03/20/2024 | 67.64% | Truist Securities | → $200 | Reiterates | Buy → Buy | |||
03/20/2024 | 57.59% | Piper Sandler | $171 → $188 | Reiterates | Overweight → Overweight | |||
03/15/2024 | 92.79% | Stifel | $225 → $230 | Maintains | Buy | |||
03/14/2024 | 67.64% | HC Wainwright & Co. | $204 → $200 | Maintains | Buy | |||
03/01/2024 | 92.79% | Barclays | $235 → $230 | Maintains | Overweight | |||
03/01/2024 | 9.81% | UBS | $135 → $131 | Maintains | Neutral | |||
02/29/2024 | 63.45% | RBC Capital | $195 → $195 | Reiterates | Outperform → Outperform | |||
02/29/2024 | 50.88% | Cantor Fitzgerald | $180 → $180 | Reiterates | Overweight → Overweight | |||
02/29/2024 | 42.5% | JP Morgan | $180 → $170 | Maintains | Overweight | |||
02/29/2024 | 84.41% | Needham | $225 → $220 | Maintains | Buy | |||
01/29/2024 | 96.98% | Barclays | $240 → $235 | Maintains | Overweight | |||
01/03/2024 | 34.12% | Baird | → $160 | Initiates | → Outperform | |||
12/04/2023 | 67.64% | Truist Securities | → $200 | Reiterates | Buy → Buy | |||
11/29/2023 | 88.6% | Needham | → $225 | Reiterates | Buy → Buy | |||
11/27/2023 | 13.16% | UBS | $170 → $135 | Downgrade | Buy → Neutral | |||
11/09/2023 | 60.1% | RBC Capital | $200 → $191 | Maintains | Outperform | |||
11/09/2023 | 88.6% | Needham | $226 → $225 | Maintains | Buy | |||
09/29/2023 | — | Raymond James | — | Initiates | → Market Perform | |||
08/22/2023 | 50.88% | Cantor Fitzgerald | → $180 | Reiterates | Overweight → Overweight | |||
08/14/2023 | 50.88% | Cantor Fitzgerald | $210 → $180 | Maintains | Overweight | |||
08/11/2023 | 71% | HC Wainwright & Co. | → $204 | Reiterates | Buy → Buy | |||
08/10/2023 | 81.89% | B of A Securities | $204 → $217 | Maintains | Buy | |||
08/10/2023 | 68.48% | RBC Capital | $203 → $201 | Maintains | Outperform | |||
08/10/2023 | 89.44% | Needham | → $226 | Reiterates | Buy → Buy | |||
08/07/2023 | 89.44% | Needham | → $226 | Reiterates | Buy → Buy | |||
07/11/2023 | 56.75% | Morgan Stanley | $187 → $187 | Reiterates | Equal-Weight → Equal-Weight | |||
06/05/2023 | 89.44% | Needham | → $226 | Reiterates | Buy → Buy | |||
05/30/2023 | 89.44% | Needham | $212 → $226 | Reiterates | Buy → Buy | |||
05/15/2023 | 71% | HC Wainwright & Co. | → $204 | Reiterates | Buy → Buy | |||
05/15/2023 | 77.7% | Needham | → $212 | Reiterates | Buy → Buy | |||
05/11/2023 | 69.32% | RBC Capital | $207 → $202 | Maintains | Outperform | |||
05/11/2023 | 77.7% | Needham | $205 → $212 | Maintains | Buy | |||
03/06/2023 | 71% | HC Wainwright & Co. | → $204 | Reiterates | → Buy | |||
03/03/2023 | 77.7% | Goldman Sachs | $190 → $212 | Maintains | Buy | |||
03/02/2023 | 71.84% | Needham | $210 → $205 | Maintains | Buy | |||
12/09/2022 | 59.26% | Goldman Sachs | $192 → $190 | Upgrade | Neutral → Buy | |||
11/10/2022 | 60.94% | Goldman Sachs | $170 → $192 | Maintains | Neutral | |||
11/10/2022 | 73.51% | RBC Capital | $206 → $207 | Maintains | Outperform | |||
11/10/2022 | 74.35% | Needham | $210 → $208 | Maintains | Buy | |||
09/29/2022 | 42.5% | Goldman Sachs | $148 → $170 | Maintains | Neutral | |||
09/21/2022 | 24.06% | Goldman Sachs | $192 → $148 | Maintains | Neutral |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Jazz Pharmaceuticals (JAZZ)?
El último precio objetivo de Jazz Pharmaceuticals (NASDAQ:JAZZ) fue comunicado por Needham el agosto 20, 2025. La firma de analistas fijó un precio objetivo para $202.00 que espera JAZZ a rise dentro de 12 meses (un posible 69.32% upside). 37 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Jazz Pharmaceuticals (JAZZ)?
La última calificación de analistas para Jazz Pharmaceuticals (NASDAQ:JAZZ) fue proporcionada por Needham, y Jazz Pharmaceuticals reiterado su buy calificación.
¿Cuándo se produjo la última revisión al alza de Jazz Pharmaceuticals (JAZZ)?
La última revisión al alza de Jazz Pharmaceuticals PLC se produjo en marzo 7, 2025, cuando UBS elevó su precio objetivo a $179. UBS anteriormente tenía a neutral para Jazz Pharmaceuticals PLC.
¿Cuándo fue la última revisión a la baja de Jazz Pharmaceuticals (JAZZ)?
La última revisión a la baja de Jazz Pharmaceuticals PLC se produjo en febrero 26, 2025, cuando Cantor Fitzgerald cambió su precio objetivo de $140 a $150 para Jazz Pharmaceuticals PLC.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Jazz Pharmaceuticals (JAZZ)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Jazz Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Jazz Pharmaceuticals se registró el agosto 20, 2025, por lo que la próxima calificación estará disponible en torno al agosto 20, 2026.
¿Es correcta la calificación de los analistas sobre Jazz Pharmaceuticals (JAZZ)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Jazz Pharmaceuticals (JAZZ) fue un reiterado con un precio objetivo de $202.00 a $202.00. El precio actual al que cotiza Jazz Pharmaceuticals (JAZZ) es de $119.30, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.